Novartis to acquire Excellergy
Novartis is to expand its role in the treatment of allergies with the acquisition of a US company specialising in therapies for diseases driven by immunoglobulin E (IgE). The target company, Excellergy Inc, was only launched in October 2025, but with Red Tree Venture Capital as a seed investor and scientists from Stanford University, US, and the University of Bern, Switzerland, working in the background, it has produced a monoclonal antibody that is already in Phase 1.
